Microfluidic methods for non-viral gene delivery

Current Gene Therapy

Volumn 15, Issue 1, 2015, Pages 55-63

  Lai, Wing Fu ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Droplet; Gene delivery; Gene therapy; Microfabrication; Microfluidics

Indexed keywords

AQUEOUS SOLUTION; ARTICLE; CELL ENCAPSULATION; CELL VIABILITY; CLINICAL TRIAL (TOPIC); ELECTROOSMOSIS; ELECTROPORATION; GENE EXPRESSION; HUMAN; LIPOFECTION; MICROFLUIDICS; MOLECULAR BIOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYFECTION; GENE THERAPY; GENE TRANSFER; IMMOBILIZED CELL; PARTICLE SIZE; PROCEDURES;

CELLS, IMMOBILIZED; ELECTROPORATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; MICROFLUIDICS; PARTICLE SIZE;

EID: 84926388101     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666141114213915     Document Type: Article

References (105)

1. [1] Ivatt RM, Sanchez-Martinez A, Godena VK, Brown S, Ziviani E, Whitworth AJ. Genome-wide RNAi screen identifies the Parkinson disease GWAS risk locus SREBF1 as a regulator of mitophagy. Proc Natl Acad Sci U S A 2014;111(23):8494-9.
2. [2] van der Sijde MR, Ng A, Fu J. Systems genetics: from GWAS to disease pathways. Biochim Biophys Acta 2014;1842(10):1903-9.
3. [3] Ramanan VK, Saykin AJ. Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. Am J Neurodegener Dis 2013;2(3):145-75.
4. [4] Simmonds MJ. GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis. Nat Rev Endocrinol 2013;9(5):277-87.
5. [5] Blalock E, Chen KC, Foster T, Landfield P. Biomarkers for aging. 2010. US 7739056 B2
6. [6] Bednarski MD, Guccione S, Li KC. Targeted cross-linked nanoparticles and their use in vivo gene delivery patent. 2012. US 8163305 B2.
7. [7] Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli- responsive nanocarriers for drug and gene delivery. J Control Release 2008; 126(3):187-204.
8. [8] Lai WF. Delivery of therapeutics: current status and its relevance to regenerative innovations. Recent Pat Nanomed 2011;1(1):7-18.
9. [9] Lai WF. In vivo nucleic acid delivery with PEI and its derivatives: current status and perspectives. Expert Rev Med Devices 2011;8(2):173-85.
10. [10] Lai WF, Lin MC. Nucleic acid delivery with chitosan and its derivatives. J Control Release 2009;134(3):158-68.
11. [11] Lai WF. Nucleic acid delivery: roles in biogerontological interventions. Ageing Res Rev 2013;12(1):310-5.
12. [12] Lai WF. Cyclodextrins in non-viral gene delivery. Biomaterials 2014;35(1):401-11.
13. [13] Janasek D, Franzke J, Manz A. Scaling and the design of miniaturized chemical-analysis systems. Nature 2006;442(7101):374-80.
14. [14] Birch L, Archard CL, Parkes HC, McDowell DG. Evaluation of LabChipTM technology for GMO analysis in food. Food Control 2001;12(8):535-40.
15. [15] Jahn A, Lucas F, Wepf RA, Dittrich PS. Freezing continuous-flow self-assembly in a microfluidic device: toward imaging of liposome formation. Langmuir 2013;29(5):1717-23.
16. [16] Kim J, Hwang I, Britain D, Chung TD, Sun Y, Kim DH. Microfluidic approaches for gene delivery and gene therapy. Lab Chip 2011;11(23):3941-8.
17. [17] Fox MB, Esveld DC, Valero A, et al. Electroporation of cells in microfluidic devices: a review. Anal Bioanal Chem 2006;385(3):474-85.
18. [18] Valero A, Post JN, van Nieuwkasteele JW, Ter Braak PM, Kruijer W, van den Berg A. Gene transfer and protein dynamics in stem cells using single cell electroporation in a microfluidic device. Lab Chip 2008;8(1):62-7.
19. [19] Weibel DB, Whitesides GM. Applications of microfluidics in chemical biology. Curr Opin Chem Biol 2006;10(6):584-91.
20. [20] Andreev VP. Cytoplasmic electric fields and electroosmosis: possible solution for the paradoxes of the intracellular transport of biomolecules. PLoS One 2013;8(4):e61884.
21. [21] Yoshina-Ishii C, Boxer SG. Controlling two-dimensional tethered vesicle motion using an electric field: interplay of electrophoresis and electro-osmosis. Langmuir 2006;22(5):2384-91.
22. [22] Washizu M. Biological applications of electrostatic surface field effects. J Electrostat 2005;63(6-10):795-802.
23. [23] Valero A, Merino F, Wolbers F, et al. Apoptotic cell death dynamics of HL60 cells studied using a microfluidic cell trap device. Lab Chip 2005;5(1):49-55.
24. [24] MacInnes JM. Computation of reacting electrokinetic flow in microchannel geometries. Chem Eng Sci 2002;57(21):4539-58.
25. [25] Kim SK, Kim JH, Kim KP, Chung TD. Continuous low-voltage dc electroporation on a microfluidic chip with polyelectrolytic salt bridges. Anal Chem 2007;79(20):7761-6.
26. [26] Fei Z, Wang S, Xie Y, Henslee BE, Koh CG, Lee LJ. Gene transfection of mammalian cells using membrane sandwich electroporation. Anal Chem 2007;79(15):5719-22.
27. [27] Wang S, Zhang X, Wang W, Lee LJ. Semicontinuous flow electroporation chip for high-throughput transfection on mammalian cells. Anal Chem 2009;81(11):4414-21.
28. [28] Zhan Y, Wang J, Bao N, Lu C. Electroporation of cells in microfluidic droplets. Anal Chem 2009;81(5):2027-31.
29. [29] Almofti MR, Harashima H, Shinohara Y, Almofti A, Li W, Kiwada H. Lipoplex size determines lipofection efficiency with or without serum. Mol Membr Biol 2003;20(1):35-43.
30. [30] Düzgüneş N, de Ilarduya CT. Genetic nanomedicine: gene delivery by targeted lipoplexes. Methods Enzymol 2012;509:355-67.
31. [31] Zhang XX, McIntosh TJ, Grinstaff MW. Functional lipids and lipoplexes for improved gene delivery. Biochimie 2012;94(1):42-58.
32. [32] Xiong F, Mi Z, Gu N. Cationic liposomes as gene delivery system: transfection efficiency and new application. Die Pharmazie 2011;66(3):158-64.
33. [33] Balazs DA, Godbey W. Liposomes for use in gene delivery. J Drug Deliv 2011;2011:326497.
34. [34] Jahn A, Vreeland WN, DeVoe DL, Locascio LE, Gaitan M. Microfluidic directed formation of liposomes of controlled size. Langmuir 2007;23(11):6289-93.
35. [35] Huang X, Caddell R, Yu B, et al. Ultrasound-enhanced microfluidic synthesis of liposomes. Anticancer Res 2010;30(2):463-6.
36. [36] Hood RR, Kendall EL, Junqueira M, et al. Microfluidic-enabled liposomes elucidate size-dependent transdermal transport. PLoS One 2014;9(3):e92978.
37. [37] Vogt A, Combadiere B, Hadam S, et al. 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol 2006;126(6):1316-22.
38. [38] Kuchler S, Radowski MR, Blaschke T, et al. Nanoparticles for skin penetration enhancement - a comparison of a dendritic coremultishell- nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm 2009;71(2):243-50.
39. [39] Kogure K, Moriguchi R, Sasaki K, Ueno M, Futaki S, Harashima H. Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J Control Release 2004;98(2):317-23.
40. [40] Ishitsuka T, Akita H, Harashima H. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung. J Control Release 2011;154(1):77-83.
41. [41] Hatakeyama H, Akita H, Harashima H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 2011;63(3):152-60.
42. [42] Khalil IA, Kogure K, Futaki S, et al. Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Ther 2007;14(8):682-9.
43. [43] Kogure K, Akita H, Yamada Y, Harashima H. Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system. Adv Drug Deliv Rev 2008;60(4-5):559-71.
44. [44] Kitazoe K, Wang J, Kaji N, et al. A touch-and-go lipid wrapping technique in microfluidic channels for rapid fabrication of multifunctional envelope-type gene delivery nanodevices. Lab Chip 2011;11(19):3256-62.
45. [45] Young AT, Lakey JR, Murray AG, Moore RB. Gene therapy: a lipofection approach for gene transfer into primary endothelial cells. Cell Transplant 2002;11(6):573-82.
46. [46] Hargest R, Eldin A, Williamson R. Gene therapy for familial adenomatous polyposis. Adv Exp Med Biol 1998;451:385-91.
47. [47] Houchin-Ray T, Whittlesey KJ, Shea LD. Spatially patterned gene delivery for localized neuron survival and neurite extension. Mol Ther 2007;15(4):705-12.
48. [48] Koh CG, Kang X, Xie Y, et al. Delivery of polyethylenimine/DNA complexes assembled in a microfluidics device. Mol Pharm 2009;6(5):1333-42.
49. [49] Song Y, Hormes J, Kumar CS. Microfluidic synthesis of nanomaterials. Small 2008;4(6):698-711.
50. [50] DeMello AJ. Control and detection of chemical reactions in microfluidic systems. Nature 2006;442(7101):394-402.
51. [51] Song H, Chen DL, Ismagilov RF. Reactions in droplets in microfluidic channels. Angew Chem Int Ed Engl 2006;45(44):7336-56.
52. [52] Daneshvar N, Abdullah R, Shamsabadi FT, How CW, Mh MA, Mehrbod P. PAMAM dendrimer roles in gene delivery methods and stem cell research. Cell Biol Int 2013;37(5):415-9.
53. [53] Braun CS, Vetro JA, Tomalia DA, Koe GS, Koe JG, Middaugh CR. Structure/function relationships of polyamidoamine/DNA dendrimers as gene delivery vehicles. J Pharm Sci 2005;94(2):423-36.
54. [54] Hui Z, He ZG, Zheng L, Li GY, Shen SR, Li XL. Studies on polyamidoamine dendrimers as efficient gene delivery vector. J Biomater Appl 2008;22(6):527-44.
55. [55] Lai WF, Jung HS. Cell transfection with a β-cyclodextrin-PEIpropane- 1,2,3-triol nanopolymer. PLoS One 2014;9(6):e100258.
56. [56] Li Y, Zhu Y, Xia K, et al. Dendritic poly(L-lysine)-b-poly(Llactide)- b-dendritic poly(L-lysine) amphiphilic gene delivery vectors: roles of PLL dendritic generation and enhanced transgene efficacies via termini modification. Biomacromolecules 2009;10(8):2284-93.
57. [57] Mousazadeh M, Palizban A, Salehi R, Salehi M. Gene delivery to brain cells with apoprotein E derived peptide conjugated to polylysine (apoEdp-PLL). J Drug Target 2007;15(3):226-30.
58. [58] Lai WF, Tang GP, Wang X, et al. Cyclodextrin-PEI-Tat polymer as a vector for plasmid DNA delivery to placenta mesenchymal stem cells. Bionanoscience 2011;1(3):89-96.
59. [59] Grigsby CL, Ho YP, Lin C, Engbersen JF, Leong KW. Microfluidic preparation of polymer-nucleic acid nanocomplexes improves nonviral gene transfer. Sci Rep 2013;3:3155.
60. [60] Folini M, Pennati M, Zaffaroni N. RNA interference-mediated validation of genes involved in telomere maintenance and evasion of apoptosis as cancer therapeutic targets. Methods Mol Biol 2009;487:303-30.
61. [61] Day TW, Safa AR. RNA interference in cancer: targeting the antiapoptotic protein c-FLIP for drug discovery. Mini Rev Med Chem 2009;9(6):741-8.
62. [62] He S, Zhang D, Cheng F, Gong F, Guo Y. Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Mol Biol Rep 2009;36(8):2153-63.
63. [63] Ferrari S, Pettenazzo A, Garbati N, Zacchello F, Behr JP, Scarpa M. Polyethylenimine shows properties of interest for cystic fibrosis gene therapy. Biochim Biophys Acta 1999;1447(2-3):219-25.
64. [64] Fajac I, Briand P, Monsigny M, Midoux P. Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cells. Hum Gene Ther 1999;10(3):395-406.
65. [65] El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release 2004;94(1):1-14.
66. [66] Itoh Y, Maruyama N, Kitamura M, Shirasawa T, Shigemoto K, Koike T. Induction of endogenous retroviral gene product (SU) as an acute-phase protein by IL-6 in murine hepatocytes. Clin Exp Immunol 1992;88(2):356-9.
67. [67] Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998;16(1):165-72.
68. [68] Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999;401(6753):517-8.
69. [69] Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003;10(11):935-40.
70. [70] Cole A. Child in gene therapy programme develops leukaemia. Brit Med J 2008;336(7634):13.
71. [71] Hargreaves S. Rules on gene therapy are tightened after-leukaemia alert. Brit Med J 2002;325(7368):791.
72. [72] Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposomemediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001;19(14):3422-33.
73. [73] Heller LC, Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010;10(4):312-7.
74. [74] Orive G, Hernández RM, Gascón AR, et al. Cell encapsulation: promise and progress. Nat Med 2003;9(1):104-7.
75. [75] de Vos P, Bucko M, Gemeiner P, et al. Multiscale requirements for bioencapsulation in medicine and biotechnology. Biomaterials 2009;30(13):2559-70.
76. [76] Orive G, Santos E, Pedraz JL, Hernandez RM. Application of cell encapsulation for controlled delivery of biological therapeutics. Adv Drug Deliv Rev 2014;67-68:3-14.
77. [77] Orive G, De Castro M, Ponce S, et al. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules. Mol Ther 2005;12(2):283-9.
78. [78] Schoeman RM, Kemna EW, Wolbers F, van den Berg A. Highthroughput deterministic single-cell encapsulation and droplet pairing, fusion, and shrinkage in a single microfluidic device. Electrophoresis 2014; 35(2-3):385-92.
79. [79] Hood RR, Shao C, Omiatek DM, Vreeland WN, DeVoe DL. Microfluidic synthesis of PEG- and folate-conjugated liposomes for one-step formation of targeted stealth nanocarriers. Pharm Res 2013;30(6):1597-607.
80. [80] Clausell-Tormos J, Lieber D, Baret JC, et al. Droplet-based microfluidic platforms for the encapsulation and screening of Mammalian cells and multicellular organisms. Chem Biol 2008;15(5):427-37.
81. [81] Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996;2(6):696-9.
82. [82] Cury-Boaventura MF, Gorjão R, de Lima TM, et al. Toxicity of a soybean oil emulsion on human lymphocytes and neutrophils. JPEN J Parenter Enteral Nutr 2006;30(2):115-23.
83. [83] Palamakula A, Khan MA. Evaluation of cytotoxicity of oils used in coenzyme Q10 Self-Emulsifying Drug Delivery Systems (SEDDS). Int J Pharm 2004;273(1–2):63-73.
84. [84] Said T, Dutot M, Christon R, et al. Benefits and side effects of different vegetable oil vectors on apoptosis, oxidative stress, and P2X7 cell death receptor activation. Invest Ophthalmol Vis Sci 2007;48(11):5000-6.
85. [85] Sikkema J, de Bont JA, Poolman B. Mechanisms of membrane toxicity of hydrocarbons. Microbiol Rev 1995;59(2):201-22.
86. [86] Hardt S, Hahn T. Microfluidics with aqueous two-phase systems. Lab Chip 2012;12(3):434-42.
87. [87] Cabral JM. Cell partitioning in aqueous two-phase polymer systems. Adv Biochem Eng Biotechnol 2007;106: 151-71.
88. [88] Giraldo-Zuniga AD, dos Reis Coimbra JS, Arquete DA, Minim LA, da Silva LHM, Maffia MC. Interfacial tension and viscosity for poly(ethylene glycol) + maltodextrin aqueous two-phase systems. J Chem Eng Data 2006;51(3):1144-7.
89. [89] Ding P, Wolf B, Frith WJ, Clark AH, Norton IT, Pacek AW. Interfacial tension in phase-separated gelatin/dextran aqueous mixtures. J Colloid Interface Sci 2002;253(2):367-76.
90. [90] Simeone M, Alfani A, Guido S. Phase diagram, rheology and interfacial tension of aqueous mixtures of Na-caseinate and Naalginate. Food Hydrocoll 2004;18(3):463-70.
91. [91] Ziemecka I, van Steijn V, Koper GJ, et al. Monodisperse hydrogel microspheres by forced droplet formation in aqueous two-phase systems. Lab Chip 2011;11(4):620-4.
92. [92] Sarei F, Dounighi NM, Zolfagharian H, Khaki P, Bidhendi SM. Alginate nanoparticles as a promising adjuvant and vaccine delivery system. Indian J Pharm Sci 2013;75(4):442-9.
93. [93] Narra K, Dhanalekshmi U, Rangaraj G, et al. Effect of formulation variables on rifampicin loaded alginate beads. Iran J Pharm Res 2012;11(3):715-21.
94. [94] Yoksan R, Jirawutthiwongchai J, Arpo K. Encapsulation of ascorbyl palmitate in chitosan nanoparticles by oil-in-water emulsion and ionic gelation processes. Colloids Surf B Biointerfaces 2010;76(1):292-7.
95. [95] Helfrich MR, El-Kouedi M, Etherton MR, Keating CD. Partitioning and assembly of metal particles and their bioconjugates in aqueous two-phase systems. Langmuir 2005;21(18):8478-86.
96. [96] Shi X, Lin LI, Chen SY, Chao SH, Zhang W, Meldrum DR. Realtime PCR of single bacterial cells on an array of adhering droplets. Lab Chip 2011;11(13):2276-81.
97. [97] Wheeler AR, Moon H, Bird CA, et al. Digital microfluidics with in-line sample purification for proteomics analyses with MALDIMS. Anal Chem 2005;77(2):534-40.
98. [98] Zenobi R. Single-cell metabolomics: analytical and biological perspectives. Science 2013;342(6163):1243259.
99. [99] Ryley J, Pereira-Smith OM. Microfluidics device for single cell gene expression analysis in Saccharomyces cerevisiae. Yeast 2006;23(14-15):1065-73.
100. [100] Valencia PM, Farokhzad OC, Karnik R, Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol 2012;7(10):623-9.
101. [101] Barbulovic-Nad I, Yang H, Park PS, Wheeler AR. Digital microfluidics for cell-based assays. Lab Chip 2008;8(4):519-26.
102. [102] Cai L, Friedman N, Xie XS. Stochastic protein expression in individual cells at the single molecule level. Nature 2006;440(7082):358-62.
103. [103] Sharei A, Zoldan J, Adamo A, et al. A vector-free microfluidic platform for intracellular delivery. Proc Natl Acad Sci U S A 2013;110(6):2082-7.
104. [104] Pessi J, Santos HA, Miroshnyk I, Jouko Yliruusi, Weitz DA, Mirza S. Microfluidics-assisted engineering of polymeric microcapsules with high encapsulation efficiency for protein drug delivery. Int J Pharm 2014;472(1-2):82-7.
105. [105] Huang H, Wei Z, Huang Y, et al. An efficient and high-throughput electroporation microchip applicable for siRNA delivery. Lab Chip 2011;11(1):163-72.